Valiant Labs Posts Q4 FY26 Audited Results, Reports Profit Growth
Valiant Laboratories Limited announced its audited Q4 FY26 results. Standalone profit after tax was ₹353.28 lakhs for the quarter and ₹554.82 lakhs for the year. Consolidated net profit after tax was ₹175.87 lakhs for the quarter, with a net loss of ₹326.79 lakhs for the year. The board meeting was held on May 14, 2026.
The announcement of financial results is material for investors. The positive turnaround in standalone performance and the improvement in quarterly consolidated performance suggest a positive impact, though the full-year consolidated loss tempers the overall impact.
The standalone results show a significant improvement in profitability for both the quarter and the full year, moving from a loss to a profit. While consolidated results still show a net loss for the year, the quarterly performance has seen a substantial turnaround.
Valiant Laboratories Limited has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors considered and approved these results, along with the audit report issued by Raman S. Shah & Co., Chartered Accountants.
The Board Meeting commenced at 3:30 PM and concluded at 5:30 PM on May 14, 2026. The company operates as a single-segment entity, focusing on chemical manufacturing.
For the standalone results, the company reported a profit after tax of ₹353.28 lakhs for the quarter ended March 31, 2026, a significant increase from ₹3.30 lakhs in the previous year's quarter. For the full year ended March 31, 2026, the standalone profit after tax stood at ₹554.82 lakhs, compared to a loss of ₹215.02 lakhs in the prior year.
On a consolidated basis, the net profit after tax for the quarter ended March 31, 2026, was ₹175.87 lakhs, a substantial improvement from a loss of ₹705.62 lakhs in the corresponding quarter of the previous year. The consolidated net profit after tax for the full year ended March 31, 2026, was a loss of ₹326.79 lakhs, compared to a loss of ₹220.12 lakhs in the previous year.
The company also confirmed that the statutory auditors have issued an unmodified opinion on the audited standalone and consolidated financial results for the financial year ended March 31, 2026.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.